Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 17, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

IgA-Enriched Phenotype Predicts Liver-Related Events in MASLD.

Takefumi Kimura1, Shun-Ichi Wakabayashi2, Takanobu Iwadare2

  • 1Department of Medicine, Division of Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan; Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Japan; Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan.

Journal of Hepatology
|July 15, 2026
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrosis-3 Index: A New Score to Predict Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Without Age as a Factor.

Gastro hep advances·2024
Same author

Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD.

Gastro hep advances·2024
Same author

The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C.

Gastro hep advances·2024
Same author

Analysis of Carcinogenic Involvement of MicroRNA Pattern in Peripheral Non-Cancerous Tissues and Chronic Viral Liver Injury.

International journal of molecular sciences·2024
Same author

A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease.

European journal of internal medicine·2024
Same author

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.

Journal of clinical and translational hepatology·2024
Summary

A new metabolic dysfunction-associated steatotic liver disease (MASLD) subtype with high IgA levels shows increased liver-related events. This IgA-driven immune activation along the gut-liver axis identifies a high-risk MASLD group for targeted therapy.

Area of Science:

  • Hepatology
  • Immunology
  • Genomics

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) is complex and requires personalized treatment strategies.
  • Stratifying MASLD patients by distinct disease mechanisms and prognosis is crucial for effective therapy.

Purpose of the Study:

  • To identify distinct patient subgroups within MASLD using unbiased clustering.
  • To characterize the biological features and prognostic implications of identified MASLD subgroups.

Main Methods:

  • Unbiased clustering analysis of 349 MASLD patients based on clinical variables.
  • Multi-omics analyses including spatial transcriptomics, scRNA-seq, and immunohistochemistry.
  • Validation in independent patient cohorts using elastography and multicenter data.
Keywords:
IGHA1fibrosisgut-liver axisintestinal permeabilitymachine learningspatial transcriptomics

Related Experiment Videos

Last Updated: Jul 17, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Main Results:

  • Four MASLD subgroups were identified; one exhibited a significantly higher 5-year incidence of liver-related events (LRE), independent of fibrosis.
  • This high-risk subgroup displayed an immune-driven phenotype with excessive IgA expression, linked to gut permeability and gut-liver axis activation.
  • Elevated IgA (≥ 318 mg/dL) was identified as an independent predictor of LRE, validated across multiple cohorts.

Conclusions:

  • A data-driven approach identified a novel MASLD subtype characterized by IgA-mediated immune activation.
  • This IgA-based stratification enhances risk assessment for MASLD progression.
  • Findings enable mechanism-based therapeutic targeting for high-risk MASLD patients.